About
Since the completion of the Human Genome Project nearly a decade ago, technological and scientific progress in the fields of genomics and personalized medicine continues to accelerate, with the next generation of human genomic research seeking to untangle the complex relationship between genes and traits and realize the promise of personalized medicine. As these fields have grown, researchers, entrepreneurs and established companies have all enjoyed increasing public and media attention – along with the attention of politicians, regulators, and judges, who are bringing a new layer of complexity to an already complicated legal and regulatory framework.
To help make sense of the resulting confusion, Robinson, Bradshaw & Hinson launched the Genomics Law Report. The Genomics Law Report focuses on the legal implications of important developments in the fields of genomics and personalized medicine — including key litigation, legislative, regulatory and policymaking activities — in order to facilitate understanding of the complicated and shifting legal landscape governing genomic and personalized medicine commerce and research.
The Genomics Law Report is designed to enable you to follow these developments as we see them, from a legal perspective, and facilitate the exchange of information and ideas within the genomics and personalized medicine communities.
If you’d like to learn more about the Genomics Law Report, would like to contribute or have a suggestion for what you’d like to see us cover, please feel free to send us a message at genomicslawreport@rbh.com. In the meantime, welcome and thank you!
GLR Editor
 |
Daniel B. Vorhaus Dan Vorhaus advises genomics and biotechnology researchers, entrepreneurs, companies and investors on legal compliance and commercialization strategies. Full Bio |
GLR Contributors
 |
Allain C. Andry Allain Andry chairs the firm’s Life Sciences practice group and represents investors and lenders in transactions in the pharmaceutical, medical device, insurance and healthcare data fields. He also represents manufacturers of pharmaceutical, nutraceutical and nutritional products in their financing, licensing and distribution transactions. Full Bio |
 |
Robert M. Bryan Bob Bryan chairs the firm’s intellectual property group and has extensive experience in acquisitions, joint ventures and licenses involving patents, trademarks and other intellectual property. Full Bio |
 |
Peter C. Buck Peter Buck practices in the areas of mergers and acquisitions and corporate and commercial law, and has extensive experience advising emerging growth companies and in in private equity and venture capital financings and buyouts. Full Bio |
 |
John M. Conley John Conley is Kenan Professor of Law at the University of North Carolina and of counsel to Robinson, Bradshaw & Hinson, where he specializes in intellectual property and biotechnology. Full Bio |
 |
Danielle L. Conrad Danielle Conrad practices in the area of corporate and real estate law and has experience advising healthcare entities with respect to joint ventures, acquisitions and real estate matters. Full Bio |
 |
Adam K. Doerr Adam Doerr represents companies and individuals involved in litigation, with an interest in the complex privacy, liability, and other legal issues arising from the field of genomics. Full Bio |
 |
Jeffrey C. Hart Jeffrey Hart is co-chair of the firm’s Venture Capital and Emerging Growth Companies practice group and has substantial experience representing both investors and companies in life sciences and biotechnology investments. Full Bio |
 |
Lawrence C. Moore, III Lawrence Moore is a civil litigator with experience in intellectual property, biotechnology, and antitrust matters. Full Bio |
 |
Kate E. Payerle Kate Payerle monitors regulatory and legislative developments in the field of genomics and is a litigator with an interest in intellectual property and tort matters. Full Bio |
 |
Emily Sherlock Emily Sherlock practices in the area of corporate law and has experience advising genomics and healthcare entities with respect to information privacy and disclosure laws. Full Bio |
 |
E. Thomas Watson Tom Watson primarily represents companies in protecting their trademarks, but he has represented clients in a variety of intellectual property and technology matters. Full Bio |
